The earnings call reveals a positive outlook for Veracyte, with strong revenue growth driven by Decipher and Afirma tests, successful launch of new products, and an impressive cash position. However, there are challenges such as a decline in product revenue and the impact of the Veracyte SAS sale on future margins.

Company Guidance

During the Veracyte Second Quarter 2025 Financial Results Webcast, the company reported a 14% year-over-year revenue growth for Q2, reaching $130 million, driven by a 14% increase in testing revenue, which adjusted to 16% excluding Envisia. Decipher's 25,500 tests represented a 28% volume growth, marking its 13th consecutive quarter of over 25% year-over-year volume growth. The company achieved an adjusted EBITDA margin of 27.5%, surpassing expectations. The Decipher test is projected to exceed 100,000 annual tests and holds a market share of 65% in the prostate testing space. Afirma also saw an 8% increase in volume year-over-year. Veracyte is transitioning Afirma to a more cost-effective sequencing technology and plans to launch Prosigna as an LDT for breast cancer by mid-2026. The company also outlined its strategy to expand its MRD platform, with the first indication being muscle-invasive bladder cancer in 2026 and plans for further expansion starting in 2027. Veracyte raised its 2025 testing revenue guidance to $477-$483 million and increased the adjusted EBITDA margin guidance to 23.5%.

Strong Revenue Growth

Veracyte delivered 14% revenue growth year-over-year with total revenue of $130 million. Testing revenue grew 14% year-over-year, or 16% when adjusted for Envisia.

Decipher Volume Growth

Decipher tests delivered approximately 25,500 tests, resulting in a year-over-year volume growth of 28%, marking the 13th consecutive quarter of over 25% year-over-year volume growth.

Adjusted EBITDA Margin Exceeds Expectations

Veracyte achieved an adjusted EBITDA margin of 27.5%, vastly exceeding expectations.

Successful Launch of Decipher Prostate Test

The Decipher Prostate test was launched for use in the metastatic population, with positive feedback from physicians and potential guideline inclusion in the coming years.

Afirma Volume Growth

Afirma’s volume growth increased 8% year-over-year, with approximately 16,950 tests conducted.

Cash Position

The company ended the quarter with $320.7 million in cash and cash equivalents.

Veracyte (VCYT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VCYT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	0.32 / -	0.19	―	―	―
Aug 06, 2025	2025 (Q2)	0.26 / 0.44	0.07	528.57% (+0.37)
May 07, 2025	2025 (Q1)	0.12 / 0.31	-0.02	1650.00% (+0.33)
Feb 24, 2025	2024 (Q4)	0.11 / 0.06	-0.39	115.38% (+0.45)
Nov 06, 2024	2024 (Q3)	0.03 / 0.19	-0.41	146.34% (+0.60)
Aug 06, 2024	2024 (Q2)	-0.02 / 0.07	-0.12	158.33% (+0.19)
May 07, 2024	2024 (Q1)	-0.16 / -0.02	-0.11	81.82% (+0.09)
Feb 22, 2024	2023 (Q4)	-0.10 / -0.39	-0.05	-680.00% (-0.34)
Nov 07, 2023	2023 (Q3)	-0.15 / -0.41	-0.12	-241.67% (-0.29)
Aug 08, 2023	2023 (Q2)	-0.15 / -0.12	-0.13	7.69% (+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VCYT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$23.97	$27.68	+15.48%
May 07, 2025	$30.84	$31.21	+1.20%
Feb 24, 2025	$39.36	$33.46	-14.99%
Nov 06, 2024	$36.59	$37.34	+2.05%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Veracyte Inc (VCYT) report earnings?

Veracyte Inc (VCYT) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is Veracyte Inc (VCYT) earnings time?

Veracyte Inc (VCYT) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VCYT EPS forecast?

VCYT EPS forecast for the fiscal quarter 2025 (Q3) is 0.32.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing